News
FBRX
1.000
0.00%
0.000
Earnings Scheduled For May 26, 2023
Benzinga · 05/26 10:28
Forte Biosciences Inc: [Amend]General statement of acquisition of beneficial ownership
Press release · 05/25 21:26
Forte Biosciences GAAP EPS of -$0.32
Seeking Alpha · 05/15 21:04
Forte Biosciences Q1 EPS $(0.32) Down From $(0.17) YoY
Benzinga · 05/15 20:33
BRIEF-Forte Biosciences Inc Announces First Quarter 2023 Results And Provides Business Update
Reuters · 05/15 20:26
Forte Biosciences Inc: Quarterly report
Press release · 05/15 16:06
BRIEF-Jec II Associates, Llc Reports 5.43% Passive Stake In Forte Biosciences As Of March 30- SEC Filing
Reuters · 04/10 13:44
Forte Biosciences GAAP EPS of -$0.80
Seeking Alpha · 04/03 04:59
Forte Biosciences, Inc. Announces FY22 Results And Provides Business Update; FY22 EPS $(0.80) Vs $(1.55) YoY
Benzinga · 03/31 20:12
BML Investment Partners Now Owns 8.26% of Forte Biosciences (FBRX)
NASDAQ · 03/29 20:28
Insider Buy: Forte Biosciences
Insider Buy: Forte Biosciences
MT Newswires · 12/19/2022 16:32
Forte Biosciences GAAP EPS of -$0.18 misses by $0.03
Seekingalpha · 11/15/2022 11:13
Forte Biosciences, Inc. - Common Stock Q3 EPS $(0.18) Up From $(0.54) YoY
Benzinga · 11/14/2022 21:32
BRIEF-Forte Biosciences Inc. Announces Third Quarter 2022 Results, Provides Business Update
Reuters · 11/14/2022 21:07
Forte Biosciences Q3 Loss Narrows
Forte Biosciences Q3 Loss Narrows
MT Newswires · 11/14/2022 16:34
BRIEF-Funicular Funds Lp Says On August 24, Sent Letter To Forte Biosciences Inc’S Board Of Directors - SEC Filing
BRIEF-Funicular Funds Lp Says On August 24, Sent Letter To Forte Biosciences Inc’S Board Of Directors - SEC Filing
Reuters · 08/24/2022 21:23
Large Forte Biosciences shareholder scolds company board of directors
Funicular Funds, which owns 8% of the outstanding shares of Forte Biosciences (NASDAQ:<a href="https://seekingalpha.com/symbol/FBRX?utm_medium=referral&utm_source=webull.com" title="Forte Biosciences, Inc....
Seekingalpha · 08/24/2022 20:47
BRIEF-Camac Partners says Forte Biosciences Board should promptly announce a plan to return capital to shareholders
BRIEF-Camac Partners says Forte Biosciences Board should promptly announce a plan to return capital to shareholders
Reuters · 08/17/2022 12:15
Camac Partners Condemns Forte Biosciences’ Seemingly Defensive and Unjustifiable Capital Raise
NEW YORK, August 17, 2022--Camac Partners, LLC (together with its affiliates, "Camac" or "we"), which is one of the largest shareholders of Forte Biosciences, Inc. (Nasdaq: FBRX) ("Forte" or the "Company"), today expressed concerns regarding the Company’s ...
Business Wire · 08/17/2022 12:00
BRIEF-Forte Biosciences Announces Q2 2022 Results
BRIEF-Forte Biosciences Announces Q2 2022 Results
Reuters · 08/15/2022 21:21
More
Webull provides a variety of real-time FBRX stock news. You can receive the latest news about Forte Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBRX
Forte Biosciences, Inc. is a biopharmaceutical company. The Company is advancing through preclinical trials its product candidate, FB-102, which is a therapeutic molecule with potentially autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo and alopecia areata (AA). FB-102 is an antagonist of autoimmune disease pathways with the potential for a durable response. The Company’s subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Emerald Limited.